Ironwood Pharmaceuticals (IRWD) AI Analysis
Score
Ironwood Pharmaceuticals doesn’t screen as a clean setup today — Stocklytics 90/100 leaves more to prove. Under the hood: P/E 5.3, about 69% below its own multi-year median, plus revenue compounding ~-10% annually over recent years.